Jan 14 (Reuters) – Structure Therapeutics said on Wednesday that it expects oral weight-loss drugs to capture 25% to 50% of the GLP-1 market by 2030, a bullish estimate the CEO said was driven partly by pent-up demand for a pill from patients and doctors.
(Reporting by Puyaan Singh in Bengaluru; Editing by Sahal Muhammed)
